Sage Therapeutics News

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Dow JonesApr 26 09:24 ET

Sage Therapeutics Is Maintained at Neutral by Mizuho

Sage Therapeutics Is Maintained at Neutral by Mizuho

Dow JonesApr 26 09:24 ET

Express News | Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

BenzingaApr 26 08:56 ET

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

TipRanksApr 26 08:35 ET

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

TipRanksApr 26 08:08 ET

SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital

TipRanksApr 26 06:37 ET

SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating

TipRanksApr 26 02:21 ET

Express News | Sage Therapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21

ReutersApr 26 01:47 ET

Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained

Sage Therapeutics (SAGE) has an average hold rating and price target range of $18 to $70, according to analysts polled by Capital IQ. Price: 13.73, Change: -0.27, Percent Change: -1.93

MT NewswiresApr 25 14:33 ET

Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty

TipRanksApr 25 14:25 ET

Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)

TipRanksApr 25 11:30 ET

Needham Reiterates Hold on Sage Therapeutics

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.

BenzingaApr 25 07:58 ET

Sage Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 — Needham Reiterates → Hold 04/18/2024 35.71% Scotiabank $34 → $19 Maintains Sector Outperform

BenzingaApr 25 07:55 ET

SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals

TipRanksApr 25 07:55 ET

SAGE Therapeutics, Inc. Q1 Loss Decreases, but Misses Estimates

RTTNewsApr 25 07:55 ET

Express News | Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time

BenzingaApr 25 06:40 ET

Express News | Sage Therapeutics Inc - Anticipates Operating Expenses Will Decrease in 2024 Relative to 2023

ReutersApr 25 06:34 ET

Express News | Sage Therapeutics Inc - Does Not Anticipate Receipt of Any Additional Milestone Payments From Collaborations in Remainder of 2024

ReutersApr 25 06:34 ET

Express News | Sage Therapeutics Inc - Net Loss Was $108.5 Mln for Q1 of 2024 Compared to $146.8 Mln for Same Period in 2023

ReutersApr 25 06:34 ET

Express News | Sage Therapeutics Inc - Achieved $6.2 Mln in Zurzuvae™ (Zuranolone) Collaboration Revenue During Q1 of 2024

ReutersApr 25 06:33 ET